Autolus Therapeutics plc Increase (Decrease) in Accounts Payable
Autolus Therapeutics plc (AUTL) reported Increase (Decrease) in Accounts Payable of -$1.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- Autolus Therapeutics plc increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$667.00K, a 143.51% decline year-over-year.
- Autolus Therapeutics plc increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$1.17M, a 163.00% decline year-over-year.
- Autolus Therapeutics plc increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$7.52M, a 2370.69% decline year-over-year.
- Autolus Therapeutics plc increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $5.42M, a 1864.13% increase year-over-year.
- Autolus Therapeutics plc increase (decrease) in accounts payable for fiscal 2025 was $1.30M, a 18.24% decline from fiscal 2024.
- Autolus Therapeutics plc increase (decrease) in accounts payable for fiscal 2024 was $1.59M.
- Autolus Therapeutics plc increase (decrease) in accounts payable for fiscal 2023 was -$509.00K, a 2413.64% decline from fiscal 2022.
- Autolus Therapeutics plc increase (decrease) in accounts payable for fiscal 2022 was $22.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$667.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.84M 10-Q · filed 2026-08-11 | -$9.36M derived: sum of 3 quarters · filed 2026-08-11 | -$3.94M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$1.17M 10-Q · filed 2026-05-14 | -$8.69M derived: sum of 2 quarters · filed 2026-05-14 | -$3.27M derived: sum of 3 quarters · filed 2026-05-14 | -$1.74M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$7.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$2.10M derived: sum of 2 quarters · filed 2026-03-27 | -$562.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.30M 10-K · filed 2026-03-27 | |
| 2025-09-30 | $5.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $6.95M derived: sum of 2 quarters · filed 2026-08-11 | $8.82M 10-Q · filed 2025-11-12 | $9.15M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.40M 10-Q · filed 2026-08-11 | $3.73M derived: sum of 3 quarters · filed 2026-08-11 | $4.00M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $1.86M 10-Q · filed 2026-05-14 | $2.19M derived: sum of 2 quarters · filed 2026-05-14 | $2.47M derived: sum of 3 quarters · filed 2026-05-14 | $2.13M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $331.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $607.00K derived: sum of 2 quarters · filed 2026-03-27 | $272.00K derived: sum of 3 quarters · filed 2026-03-27 | $1.59M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $276.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$59.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.26M 10-Q · filed 2025-11-12 | $681.00K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$335.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $983.00K 10-Q · filed 2025-08-12 | $405.00K derived: sum of 3 quarters · filed 2025-08-12 | -$2.79M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $1.32M 10-Q · filed 2025-05-08 | $740.00K derived: sum of 2 quarters · filed 2025-05-08 | -$2.45M derived: sum of 3 quarters · filed 2025-05-08 | $1.04M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$578.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$3.77M derived: sum of 2 quarters · filed 2025-03-20 | -$282.00K derived: sum of 3 quarters · filed 2025-03-20 | -$509.00K 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$3.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $296.00K derived: sum of 2 quarters · filed 2024-11-12 | $69.00K 10-Q · filed 2024-11-12 | $178.00K derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $3.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.26M 10-Q · filed 2024-08-08 | $3.37M derived: sum of 3 quarters · filed 2024-08-08 | ||
| 2023-03-31 | -$227.00K 10-Q · filed 2024-05-17 | -$118.00K derived: sum of 2 quarters · filed 2024-05-17 | |||
| 2022-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $22.00K 10-K · filed 2024-03-21 | |||
| 2022-09-30 | -$87.00K 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | -$1.82M 10-K · filed 2024-03-21 | ||||
| 2021-03-31 | -$902.00K 6-K · filed 2021-05-06 | $27.00K derived: sum of 2 quarters · filed 2023-03-07 | $1.82M derived: sum of 3 quarters · filed 2023-03-07 | $661.00K derived: sum of 4 quarters · filed 2023-03-07 | |
| 2020-12-31 | $929.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-07 | $2.72M derived: sum of 2 quarters · filed 2023-03-07 | $1.56M derived: sum of 3 quarters · filed 2023-03-07 | $1.44M 20-F · filed 2023-03-07 | |
| 2020-09-30 | $1.79M derived: 6-K 9 month − 6-K 6 month · filed 2020-11-05 | $634.00K derived: sum of 2 quarters · filed 2020-11-05 | $510.00K 6-K · filed 2020-11-05 | -$1.30M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-06-30 | -$1.16M derived: 6-K 6 month − 6-K 3 month · filed 2020-08-06 | -$1.28M 6-K · filed 2020-08-06 | -$3.09M derived: sum of 3 quarters · filed 2022-03-10 | -$3.21M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-03-31 | -$124.00K 6-K · filed 2021-05-06 | -$1.94M derived: sum of 2 quarters · filed 2022-03-10 | -$2.05M derived: sum of 3 quarters · filed 2022-03-10 | -$1.08M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2019-12-31 | -$1.81M derived: 20-F 12 month − 6-K 9 month · filed 2022-03-10 | -$1.93M derived: sum of 2 quarters · filed 2022-03-10 | -$958.00K derived: sum of 3 quarters · filed 2022-03-10 | -$1.45M 20-F · filed 2022-03-10 | |
| 2019-09-30 | -$113.00K derived: 6-K 9 month − 6-K 6 month · filed 2020-11-05 | $855.00K derived: sum of 2 quarters · filed 2020-11-05 | $362.00K 6-K · filed 2020-11-05 | -$361.00K derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-06-30 | $968.00K derived: 6-K 6 month − 6-K 3 month · filed 2020-08-06 | $475.00K 6-K · filed 2020-08-06 | -$248.00K derived: sum of 3 quarters · filed 2021-03-04 | -$4.31M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-03-31 | -$493.00K 6-K · filed 2020-05-07 | -$1.22M derived: sum of 2 quarters · filed 2021-03-04 | -$5.28M derived: sum of 3 quarters · filed 2021-03-04 | ||
| 2018-12-31 | -$723.00K 20-F · filed 2021-03-04 | -$4.79M derived: sum of 2 quarters · filed 2021-03-04 | |||
| 2018-09-30 | -$4.07M derived: 20-F 9 month − 6-K 6 month · filed 2021-03-04 | $838.00K 20-F · filed 2021-03-04 | $2.03M 6-K · filed 2019-11-07 | $838.00K 20-F · filed 2020-03-03 | |
| 2018-06-30 | $4.90M 6-K · filed 2019-08-08 | ||||
| 2017-09-30 | $434.00K 20-F · filed 2020-03-03 | ||||
| 2016-09-30 | $507.00K 20-F · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |